KMT2A and acute myeloid leukemia: Mutations of genes with adverse prognostic impact were also more frequent in our cohort as compared with unselected cases of AML, including ASXL1 (54% vs 5‐10%), RUNX1 (29% vs 5‐10%), KMT2A (27% vs 5%), TET2 (19% vs 5‐10%), and KIT (13% vs <5%).40, 45 Other gene mutations with adverse impacts were found at frequencies comparable with unselected AML, including FLT3 (33%) and TP53 (6%).